Pancreatic cancer mortality statistics

Deaths

Deaths from pancreatic cancer, 2017-2019, UK.

Proportion of all deaths

Percentage pancreatic cancer contributes to total cancer deaths, 2017-2019, UK

 

Age

Peak rate of pancreatic cancer deaths, 2017-2019, UK

 

Trend over time

Pancreatic cancer mortality rates have changed differently for each sex since the early 1970s, UK

Pancreatic cancer is the 5th most common cause of cancer death in the UK, accounting for 6% of all cancer deaths (2017-2019).[1-4]

In females in the UK, pancreatic cancer is the 5th most common cause of cancer death (6% of all female cancer deaths). In males in the UK, it is the 5th most common cause of cancer death (5% of all male cancer deaths).

49% of pancreatic cancer deaths in the UK are in females, and 51% are in males (2017-2019).

Pancreatic cancer mortality rates (European age-standardised Open a glossary item (AS) rates) in the UK are significantly lower in females than in males (2017-2019).

Pancreatic cancer mortality rates (European age-standardised Open a glossary item (AS) rates) for persons are similar to the UK average in all the UK constituent countries.

For pancreatic cancer, mortality rates do not vary between UK constituent nations however incidence rates do vary between the UK constituent nations.

Pancreatic Cancer (C25), Annual Average Number of Deaths, Crude and European Age-Standardised (AS) Mortality Rates per 100,000 Persons Population, UK, 2017-2019

  England Scotland Wales Northern Ireland UK
Female Deaths 3,921 390 251 119 4,680
Crude Rate 13.9 14.0 15.8 12.5 13.9
AS Rate 13.6 13.2 13.9 13.3 13.5
AS Rate - 95% LCL 13.3 12.4 12.9 11.9 13.3
AS Rate - 95% UCL 13.8 13.9 14.9 14.7 13.8
Male Deaths 4,078 415 256 128 4,877
Crude Rate 14.7 15.7 16.6 13.9 14.9
AS Rate 17.1 17.6 17.1 18.0 17.2
AS Rate - 95% LCL 16.8 16.7 15.9 16.2 16.9
AS Rate - 95% UCL 17.4 18.6 18.3 19.8 17.5
Persons Deaths 7,999 805 507 247 9,558
Crude Rate 14.3 14.8 16.2 13.1 14.4
AS Rate 15.2 15.2 15.4 15.4 15.2
AS Rate - 95% LCL 15.0 14.6 14.6 14.3 15.0
AS Rate - 95% UCL 15.4 15.8 16.2 16.5 15.4

95% LCL and 95% UCL are the 95% lower and upper confidence limits around the AS Rate Open a glossary item

References

  1. England and Wales data were accessed from Nomis mortality statistics by underlying cause, sex and age, November 2021: Nomis mortality statistics by underlying cause, sex and age.
  2. Scotland data were provided by ISD Scotland on request, November 2021. Similar data can be found here: http://www.isdscotland.org/Health-Topics/Cancer/Publications/index.asp(link is external).
  3. Northern Ireland data were provided by the Northern Ireland Cancer Registry on request, February 2022. Similar data can be found here: http://www.qub.ac.uk/research-centres/nicr/.
  4. Population data were published by the Office for National statistics, accessed July 2020. The data can be found here: Population estimates for the UK, England and Wales, Scotland and Northern Ireland, provisional: mid-2019.

About this data

Data is for UK, 2017-2019, C25.

Last reviewed:

Pancreatic cancer mortality is strongly related to age, with the highest mortality rates being in older people. In the UK in 2017-2019, on average each year around half of deaths (51%) were in people aged 75 and over.[1-4] This largely reflects higher incidence and lower survival for pancreatic cancer in older people.

Age-specific mortality rates rise steeply from around age 50-54. The highest rates are in the 85 to 89 age group for females and the 90+ age group for males. Mortality rates are significantly lower in females than males in a number of (mainly older) age groups. The gap is widest at age 45 to 49, when the age-specific mortality rate is 1.6 times lower in females than males.

Pancreatic Cancer (C25), Average Number of Deaths per Year and Age-Specific Mortality Rates per 100,000 Persons Population, UK, 2017-2019

References

  1. England and Wales data were accessed from Nomis mortality statistics by underlying cause, sex and age, November 2021: Nomis mortality statistics by underlying cause, sex and age.
  2. Scotland data were provided by ISD Scotland on request, November 2021. Similar data can be found here: http://www.isdscotland.org/Health-Topics/Cancer/Publications/index.asp(link is external).
  3. Northern Ireland data were provided by the Northern Ireland Cancer Registry on request, February 2022. Similar data can be found here: http://www.qub.ac.uk/research-centres/nicr/.
  4. Population data were published by the Office for National statistics, accessed July 2020. The data can be found here: Population estimates for the UK, England and Wales, Scotland and Northern Ireland, provisional: mid-2019.

About this data

Data is for UK, 2017-2019, ICD-10 C25.

Last reviewed:

Pancreatic cancer age-standardised (AS) Open a glossary item rates for females and males combined remained stable in the UK between 1971-1973 and 2017-2019.[1-4] The change varied markedly between sexes.

For females, pancreatic cancer AS mortality rates in the UK increased by 12% between 1971-1973 and 2017-2019. For males, pancreatic cancer AS mortality rates in the UK decreased by 12% between 1971-1973 and 2017-2019.

Over the last decade in the UK (between 2007-2009 and 2017-2019), pancreatic cancer AS mortality rates for females and males combined increased by 3%. In females AS mortality rates remained stable, and in males rates increased by 4%.

Pancreatic Cancer (C25), European Age-Standardised Mortality Rates per 100,000 Persons Population, UK, 1971-2019

For most cancer types, mortality trends largely reflect incidence and survival trends. For example, rising mortality may reflect rising incidence and stable survival, while falling mortality may reflect rising incidence and rising survival.

Pancreatic cancer mortality rates have varied between age groups in females in the UK since the early 1970s.[1-4] Rates in 0-24s have remained stable, in 25-49s have decreased by 36%, in 50-59s have decreased by 16%, in 60-69s have remained stable, in 70-79s have increased by 15% and in 80+s have increased by 29%.

Pancreatic Cancer (C25), European Age-Standardised Mortality Rates per 100,000 Female Population, By Age, UK, 1971-2019

Pancreatic cancer mortality rates have decreased overall in some broad age groups in males in the UK since the early 1970s, but have remained stable in others.[1-4] Rates in 0-24s have remained stable, in 25-49s have decreased by 40%, in 50-59s have decreased by 31%, in 60-69s have decreased by 21%, in 70-79s have decreased by 10% and in 80+s have remained stable.

Pancreatic Cancer (C25), European Age-Standardised Mortality Rates per 100,000 Male Population, By Age, UK, 1971-2019

References

  1. England and Wales data were accessed from Nomis mortality statistics by underlying cause, sex and age, November 2021: Nomis mortality statistics by underlying cause, sex and age.
  2. Scotland data were provided by ISD Scotland on request, November 2021. Similar data can be found here: http://www.isdscotland.org/Health-Topics/Cancer/Publications/index.asp(link is external).
  3. Northern Ireland data were provided by the Northern Ireland Cancer Registry on request, February 2022. Similar data can be found here: http://www.qub.ac.uk/research-centres/nicr/.
  4. Population data were published by the Office for National statistics, accessed July 2020. The data can be found here: Population estimates for the UK, England and Wales, Scotland and Northern Ireland, provisional: mid-2019.

About this data

Data is for UK, 1971-2019, C25.

Cancers in children and young people (aged 0-24) are best classified using a different system to cancers in adults, so the figures presented here may not correspond with those elsewhere.

Last reviewed:

It is projected that the average number of deaths from pancreatic cancer in the UK every year will rise from around 10,500 deaths in 2023-2025 to around 12,600 deaths in 2038-2040.[1]

Pancreatic cancer mortality rates are projected to fall by 4% in the UK between 2023-2025 and 2038-2040, to 15 deaths per 100,000 people on average each year by 2038-2040.[1] This includes a similar decrease for males and females.

For females, pancreatic cancer European age standardised (AS) Open a glossary item mortality rates in the UK are projected to fall by 5% between 2023-2025 and 2038-2040, to 13 deaths per 100,000 per year by 2038-2040.[1] For males, AS rates are projected to fall by 3% between 2023-2025 and 2038-2040, to 17 deaths per 100,000 per year by 2038-2040.[1]

Pancreatic cancer (C25), Observed and Projected Age-Standardised Mortality Rates, by Sex, UK, 1975-2040

Download the data (xlsx)

References

Calculated by the Cancer Intelligence Team at Cancer Research UK, February 2023. Age-period-cohort modelling approach described here, using 2020-based population projections (Office for National Statistics) and observed cancer mortality data (1975-2018).

About this data

Projections are based on mortality data from 1975-2018 (England, Scotland, Wales and Northern Ireland); the above figure presents all UK data from 1975-2018 (observed) and 2019-2040 (projected). Number of deaths and age-standardised rates are presented as annual averages for each 3-year rolling period. ICD-10 codes C25.

Projections are based on observed mortality rates and therefore implicitly include changes in cancer risk factors, diagnosis and treatment. Confidence intervals are not calculated for the projected figures. Projections are by their nature uncertain because unexpected events in future could change the trend. It is not sensible to calculate a boundary of uncertainty around these already uncertain point estimates. Changes are described as 'increase' or 'decrease' if there is any difference between the point estimates.

More on projections methodology

Last reviewed:

There is evidence for an association between pancreatic cancer mortality and deprivation for both males and females in England.[1] England-wide data for 2007-2011 show European age-standardised Open a glossary item mortality rates are 20% higher for males living in the most deprived areas compared with the least deprived, and 25% higher for females.[1]

Pancreatic Cancer (C25), European Age-Standardised Mortality Rates by Deprivation Quintile, England, 2007-2011

The estimated deprivation gradient in pancreatic cancer mortality between people living in the most and least deprived areas in England has not changed in the period 2002-2011.[1] It has been estimated that there would have been around 430 fewer cancer deaths each year in England during 2007-2011 if all people experienced the same mortality rates as the least deprived.[1]

References

  1. Cancer Research UK and National Cancer Intelligence Network. Cancer by deprivation in England: Incidence, 1996-2010, Mortality, 1997-2011. London: NCIN; 2014.

About this data

Data is for: UK, 2007-2011, ICD-10 C25

Deprivation gradient statistics were calculated using mortality data for 2007-2011. The deprivation quintiles were calculated using the Income domain scores from the Index of Multiple Deprivation (IMD) from the following years: 2004, 2007 and 2010. Full details on the data and methodology can be found in the Cancer by Deprivation in England NCIN report.

Last reviewed:

Cancer stats explained

See information and explanations on terminology used for statistics and reporting of cancer, and the methods used to calculate some of our statistics.

Citation

You are welcome to reuse this Cancer Research UK content for your own work.
Credit us as authors by referencing Cancer Research UK as the primary source. Suggested styles are:

Web content: Cancer Research UK, full URL of the page, Accessed [month] [year].
Publications: Cancer Research UK ([year of publication]), Name of publication, Cancer Research UK.
Graphics (when reused unaltered): Credit: Cancer Research UK.
Graphics (when recreated with differences): Based on a graphic created by Cancer Research UK.

When Cancer Research UK material is used for commercial reasons, we encourage a donation to our life-saving research.
Send a cheque payable to Cancer Research UK to: Cancer Research UK, 2 Redman Place, London, E20 1JQ or

Donate online

Acknowledgements

We are grateful to the many organisations across the UK which collect, analyse, and share the data which we use, and to the patients and public who consent for their data to be used. Find out more about the sources which are essential for our statistics.